EFA

A new independent survey commissioned by the European Medicines Agency (EMA) and carried out by Dr Frederic Bouder has provided several new recommendations on how the EMA – which is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union – could improve its communication on the health benefits and risks of medicines. The report analysed stakeholder expectations and used evidence-based input to develop its recommendations, which EMA said it has already begun to implement. These include improving how messages are communicated to non-expert audiences – including patient –, reviewing how and when to communicate such messages, and involving patients in communication activities on a more regular basis. Summary Report